Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Aligos Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Aligos Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Scopa James Paul | Director | 183,083 | Jun 29, 2026 | 1 |
| Preston Heather | Director | – | Jun 29, 2026 | 1 |
| Martell Bridget A | Director | – | Jun 29, 2026 | 1 |
| Nuechterlein Carole | Director | 11,025,941Indirect | Jun 29, 2026 | 1 |
| Hirth Peter | Director | – | Jun 29, 2026 | 1 |
| Chavez Margarita | Director | – | Jun 29, 2026 | 1 |
| Blatt Lawrence | President and CEO | 1,847,575 | Mar 11, 2026 | 1 |
| Calhoun Lesley Ann | See Remarks | – | Mar 11, 2026 | 1 |
| Symons Julian A. | See Remarks | – | Mar 11, 2026 | 1 |
| Aneja Nikhil | Principal Accounting Officer | – | Mar 11, 2026 | 1 |
| Achneck Hardean | Chief Medical Officer | – | Oct 10, 2024 | 0 |
| McClure Matthew W. | Chief Medical Officer | – | Mar 4, 2024 | 0 |
| Nielsen Jack | Director | – | Feb 28, 2024 | 0 |
| Quan Lucinda Y. | See Remarks | – | Sep 12, 2023 | 0 |
| Beigelman Leonid | President | – | Mar 17, 2023 | 0 |
| Woiwode Thomas | Director | – | Jun 27, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 2023 (view filing)4:15 PM ET | Oct 25 | 2 days | Nuechterlein CaroleDirector, 10% Owner | PPurchase | +7.93M | $0.7568 | +$6.00M | +256.6%11.0M after | |
| Oct 27, 2023 (view filing)4:15 PM ET | Oct 25 | 2 days | Nuechterlein CaroleDirector, 10% Owner | PPurchase | +3.97M | $0.125 | +$495.9K | –3.97M after | Derivative |